[go: up one dir, main page]

MA42048A - Dérivés d'aminoesters - Google Patents

Dérivés d'aminoesters

Info

Publication number
MA42048A
MA42048A MA042048A MA42048A MA42048A MA 42048 A MA42048 A MA 42048A MA 042048 A MA042048 A MA 042048A MA 42048 A MA42048 A MA 42048A MA 42048 A MA42048 A MA 42048A
Authority
MA
Morocco
Prior art keywords
aminoesters
derivatives
aminoesters derivatives
Prior art date
Application number
MA042048A
Other languages
English (en)
Inventor
Gabriele Amari
Elisabetta Armani
Charles Baker-Glenn
Wesley Blackaby
Naimisha Trivedi
De Pöel Hervé Van
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MA42048A publication Critical patent/MA42048A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA042048A 2015-05-07 2016-05-05 Dérivés d'aminoesters MA42048A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15166703 2015-05-07

Publications (1)

Publication Number Publication Date
MA42048A true MA42048A (fr) 2018-03-14

Family

ID=53177142

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042048A MA42048A (fr) 2015-05-07 2016-05-05 Dérivés d'aminoesters

Country Status (5)

Country Link
US (2) US9809582B2 (fr)
EP (1) EP3292118A1 (fr)
AR (1) AR104532A1 (fr)
MA (1) MA42048A (fr)
WO (1) WO2016177849A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111161344B (zh) * 2019-12-31 2021-08-10 广州永士达医疗科技有限责任公司 基于oct设备的气道弹性测量方法、系统、设备及介质
FI20225388A1 (en) 2022-05-05 2023-11-06 Equinorm Ltd New heterocyclic compounds, preparation methods and their uses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103562185A (zh) * 2011-06-06 2014-02-05 奇斯药制品公司 作为磷酸二酯酶抑制剂的1-苯基-2-吡啶基烷基醇的衍生物
CA2893649A1 (fr) * 2012-12-05 2014-06-12 Chiesi Farmaceutici S.P.A. Derives de phenylethylpyridine comme inhibiteurs de pde4
RU2015121037A (ru) 2012-12-05 2017-01-11 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Производные фенилэтилпиридина в качестве ингибиторов pde-4
EP2928880B1 (fr) 2012-12-05 2018-02-14 Chiesi Farmaceutici S.p.A. Dérivés de phenylethylpyridine comme inhibiteurs de pde4 et en tant qu'antagonistes des récepteurs muscariniques
EP3077386B1 (fr) 2013-12-05 2017-09-06 Chiesi Farmaceutici S.p.A. Dérivés de benzhydryle pour le traitement de maladies respiratoires
TW201607944A (zh) * 2013-12-05 2016-03-01 吉斯藥品公司 雜芳基衍生物
US9763924B2 (en) 2014-06-05 2017-09-19 Chiesi Farmaceutici S.P.A. Aminoester derivatives
US9326976B2 (en) 2014-06-05 2016-05-03 Chiesi Farmaceutici S.P.A. Carbamate derivatives

Also Published As

Publication number Publication date
US20160326147A1 (en) 2016-11-10
US20180016265A1 (en) 2018-01-18
WO2016177849A1 (fr) 2016-11-10
US9809582B2 (en) 2017-11-07
AR104532A1 (es) 2017-07-26
EP3292118A1 (fr) 2018-03-14

Similar Documents

Publication Publication Date Title
DK3688162T3 (da) Formuleringer
DK3319956T3 (da) Substituerede oxopyridinderivater
DK3529248T3 (da) Farmaceutiske sammensætninger
EP3464313A4 (fr) Nucléotides modifiés 5 '-cyclo-phosphonate
MA40774A (fr) Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
EP3563835A4 (fr) Nouvel agent anticancéreux à base d'exosome
EP3357054C0 (fr) Modèle d'hystérectomie
BR112017027227A2 (pt) Agente anti-câncer
DK3529240T3 (da) Farmaceutiske forbindelser
DK3244878T3 (da) Faste orale sammensætningsformer
EP3536734A4 (fr) Composition polymérisable
DK3642202T3 (da) Dihydro-pyrrolo-pyridin-derivater
EP3364945C0 (fr) Formulation solide
LT3371168T (lt) Indolin-2-ono dariniai
EP3454847A4 (fr) Formulations de médicaments améliorées
EP3431808A4 (fr) Butée d'arrêt
EP3720268A4 (fr) Cultivar de stévia '16228013'
DK3280447T3 (da) Farmaceutiske formuleringer
DK3645513T3 (da) Benzazepinderivater
EP3548425A4 (fr) Formulations de nanoparticules
MA49708A (fr) Dérivés de dihétérocycle liés à cycloalkyle
EP3416672A4 (fr) Formulations d'oritavancine
EP3312172A4 (fr) Dérivés d'aminopyrazole
MA42048A (fr) Dérivés d'aminoesters
EP3595647A4 (fr) Dérivés d'aryl-pipéridine